Nominations are now open for The Medicine Maker 2023 Power List.

Can blood cancer care be improved to ensure that patients from minority groups receive equitable treatment?

It’s time for quality and manufacturing to go paperless, but how should a company go about digitization?

The women’s health treatment landscape is devoid of relevant options. What can pharma do to improve the situation?

ISCT speaks out after US court rules that stem cell therapy does not fall under FDA jurisdiction.

Current approaches to R&D tech investment are not helping life science companies. How can the situation be improved?

Roche’s Kowid Ho talks us through a career spent shaping regulation and striving for pharmaceutical excellence.

From surge to stumble and back again, seven cell and gene legends recount their personal favorite breakthroughs in the field.

We speak to one of advanced therapy’s great minds about analog and digital events, and the future of the field.

To see continued progress, the pharma and tech industries must collaborate.